Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18213704 | 1.00 | SHBG (0.42) | SHBGCYP19A1AKR1B10AKR1B1OR51E2 | |
| SCHEMBL16010623 | 1.00 | SHBG (0.42) | SHBGCYP19A1AKR1B10AKR1B1OR51E2 | |
| SCHEMBL16010085 | 1.00 | SHBG (0.42) | SHBGCYP19A1AKR1B10AKR1B1OR51E2 | |
| SCHEMBL16020127 | 0.89 | SHBG (0.40) | SHBGCYP19A1AKR1B10AKR1B1OR51E2 | |
| SCHEMBL18213649 | 0.82 | CYP19A1 (0.38) | CYP19A1ESR2ESR1 | |
| SCHEMBL16020089 | 0.81 | CYP19A1 (0.40) | CYP19A1ESR2ESR1 | |
| SCHEMBL16020115 | 0.81 | CYP19A1 (0.40) | CYP19A1ESR2ESR1 | |
| SCHEMBL16010571 | 0.78 | GPBAR1 (0.44) | SHBG | |
| SCHEMBL16020124 | 0.78 | GPBAR1 (0.44) | SHBG | |
| SCHEMBL16020090 | 0.78 | GPBAR1 (0.44) | SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326127-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | WASHINGTON UNIVERSITY | 2016-11-10 | — | — | US | disclosed |
| US-20160326127-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | WASHINGTON UNIVERSITY | 2016-11-10 | — | — | US | disclosed |
| US-20160326127-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | WASHINGTON UNIVERSITY | 2016-11-10 | — | — | US | disclosed |
| US-9365502-B2 | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365502-B2 | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365502-B2 | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140256805-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-11 | — | — | US | disclosed |
| US-20140256805-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-11 | — | — | US | disclosed |
| US-20140256805-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256805-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRB3, GABRB1, GABRB2 | SHBG 579/4885CYP19A1 796/4885AKR1B10 1534/4885 |
| US-20160326127-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRB3, GABRB1, GABRB2 | SHBG 579/4885CYP19A1 796/4885AKR1B10 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.